CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Oxford Biomedica (OXB) signs agreement with Cancer group

By Jenny McCall

09:07, 13 December 2021

Concept picture of gene therapy for cancer treatment with T-cell and pipette
Gene and cell therapy firm signs new licence and supply agreement with Arcellx – Photo: Shutterstock

London-listed Oxford Biomedica (OXB), a gene and cell therapy company specialising in the development of gene-based medicines announced today it has signed a new licence and supply agreement (LSA) with Arcellx.

Arcellx is a biotechnology company that is developing a novel and adaptive idea for the treatment of cancer and autoimmune diseases.

The LSA would allow Arcellx a non-exclusive licence to Oxford Biomedica’s LentiVector® platform for its application in select Arcellx CAR-T programmes and put in place a three-year clinical supply agreement.

CAR T-cell therapy is an innovative approach to program the immune system to attack cancer. 

Next-generation technologies

“Arcellx is one of the leading next-generation CAR-T developers deploying a wide range of innovative technologies to bring innovative CAR-T products into development,” said John Dawson, chief executive officer of Oxford Biomedica

“We are proud to be working with a leader in the field of CAR-T that shares our vision of delivering cell and gene therapies to save lives,” he added.

According to the statement, under the terms of the LSA, Oxford Biomedica would receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials.

What is your sentiment on OXB?

1.682
Bullish
or
Bearish
Vote to see Traders sentiment!

TSLA

239.02 Price
+1.900% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.14

GME

15.36 Price
+5.850% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.16

AMZN

147.02 Price
+0.760% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.14

NVDA

467.55 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.14

Novartis extension

This partnership would build on the existing partnerships with Novartis and Bristol Myers Squibb, as well as the more recently announced partnership with Beam Therapeutics.

Oxford Biomedica announced in another update today that it agreed on an extension and update to its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for several Novartis CAR-T products.

Under the new terms, the agreement was extended until the end of 2028 and Oxford Biomedica has regained the rights to its LentiVector® platform relating to three CAR-T targets, including CD19 targeted therapies.

As a result, the group now has the right to work with potential pharmaceutical and biotechnology partners other than Novartis across all CAR-T targets.

John Dawson commented on the strategic partnership with Novartis since 2014, and said this “updated supply agreement provides both companies with greater flexibility…and allows us to react to the rapidly growing dynamics of the commercial CAR-T sector.

Oxford Biomedica’s stock price was down 2.33% in early morning trading today. 

Read more: Oxford Biomedica reports revenue jump, Serum Institute investment

Markets in this article

OXB
Oxford BioMedica plc
1.682 USD
-0.056 -3.330%
OXB
Oxford BioMedica plc
1.682 USD
-0.056 -3.330%

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading